NCPC(SH:600812)2023-08-18 16:00Financial Performance - The company's operating revenue for the first half of 2023 was ¥5,233,404,242.63, a decrease of 0.86% compared to ¥5,278,695,208.78 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was ¥26,545,580.14, down 18.01% from ¥32,375,502.36 in the previous year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥1,058,954.77, a significant decrease of 92.32% compared to ¥13,793,621.94 in the same period last year[20]. - Basic earnings per share decreased by 21.05% to CNY 0.015 compared to the same period last year[21]. - Diluted earnings per share also decreased by 21.05% to CNY 0.015 year-on-year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses dropped significantly by 87.50% to CNY 0.001 per share[21]. - The total profit for the first half of 2023 was CNY 344,814,183.91, compared to CNY 365,411,880.21 in the same period last year, indicating a decline of 5.1%[95]. - The company reported a net profit of CNY -579,957,810.86, an improvement from CNY -606,503,391.00 in the previous year[91]. - The company reported a cash balance of RMB 1,387,911,776.12 as of June 30, 2023, down from RMB 1,682,737,264.95 at the end of 2022, indicating a decrease of approximately 17.5%[75]. Cash Flow and Assets - The net cash flow from operating activities increased by 14.75% to ¥264,985,100.37 from ¥230,926,978.27 in the previous year[20]. - The total assets at the end of the reporting period were ¥21,113,767,305.29, a decrease of 0.51% from ¥21,221,017,906.40 at the end of the previous year[20]. - The company reported a cash inflow from operating activities for the first half of 2023 of CNY 4,208,784,646.04, a decrease of 6.73% compared to CNY 4,513,573,421.69 in the same period of 2022[107]. - The total current assets amounted to RMB 8,948,204,316.52, a slight decrease from RMB 8,982,898,658.97, indicating a decline of approximately 0.4%[75]. - The total cash and cash equivalents at the end of the period was CNY 1,002,806,772.24, a decrease from CNY 4,092,258,146.63 at the end of the same period last year[110]. Shareholder Information - The company reported a total shareholding of 413,080,473 shares by Hebei Zhong Energy Co., accounting for 24.08% of total shares, with no changes during the reporting period[56]. - Huabei Pharmaceutical Group holds 341,471,645 shares, representing 19.90% of total shares, with 84,925,641 shares under lock-up conditions[56]. - The total number of shares held by the top ten shareholders includes 413,080,473 shares from Jizhong Energy Co., Ltd. and 341,471,645 shares from North China Pharmaceutical Group Co., Ltd.[57]. - The company approved a three-year shareholder return plan for 2023-2025 during the annual general meeting[181]. - The company did not propose any profit distribution or capital reserve transfer plans for the reporting period[182]. Research and Development - Research and development expenses increased to CNY 141,925,060.43, up from CNY 104,406,262.56, reflecting a focus on innovation[92]. - The company experienced a decrease in financial expenses, which amounted to CNY 170,412,471.55, down from CNY 222,707,785.99, a reduction of 23.5%[95]. - The company applied for 23 patents during the reporting period, with 21 patents granted, enhancing its competitive edge[136]. - The company is focused on developing high-value and high-growth projects, particularly in biopharmaceuticals, while consolidating its position in chemical pharmaceuticals[122]. - The company aims to strengthen its advantages in the antibiotic sector, maintaining leading production scale, technology level, and product quality domestically[122]. Environmental Management - The company has committed to enhancing environmental management and compliance with ecological regulations during the reporting period[29]. - The company reported a total solid waste generation of 4,555.653 tons in the first half of 2023, all of which was disposed of in compliance with regulations[191]. - The actual discharge concentration for chemical oxygen demand (COD) was 236 mg/L, which is below the limit of 300 mg/L[190]. - The ammonia nitrogen discharge was 0.98 mg/L, significantly lower than the limit of 15 mg/L[190]. - The company adheres to the "Pharmaceutical Industry Air Pollutant Emission Standards" (GB 37823-2019) and "Odorous Pollutants Emission Standards" (GB14554-1993)[191]. Market and Strategic Focus - The company plans to continue its focus on green development and environmental protection initiatives[29]. - The company is actively seeking solutions for the operational issues faced by Tianxing Company, which has been fully suspended since January 2014 due to urban planning and environmental reasons[54]. - The company aims to enhance its international competitiveness through a unified export platform for formulations[135]. - The company is focusing on developing new treatment areas such as cardiovascular, oncology, kidney disease, and diabetes[135]. - The company has established a sales network covering most provinces and municipalities in China, utilizing a distribution and academic promotion model[129].